What was the first indigenous vaccine in India?

NORCET 2 - 2021 (shift-1)

Applied Microbiology & Infection control

Easy

Appeared in: NORCET 2 - 2021 (shift-1)

Explanation

Covaxin is recognized as India's first indigenous vaccine developed to combat the COVID-19 pandemic.
It was developed through a public-private partnership between Bharat Biotech, a Hyderabad-based biotechnology company, and the Indian Council of Medical Research (ICMR).
The vaccine uses a traditional platform of an inactivated (killed) whole virion of the SARS-CoV-2 virus.
This platform stimulates a broad immune response against the virus but cannot cause infection as the virus is not live.

Option B: Sputnik V is a Russian vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow.
Option C: Although manufactured on a large scale by the Serum Institute of India, Covishield was developed by Oxford University and the British-Swedish company AstraZeneca.
Option D: Moderna is an mRNA vaccine developed by the American biotechnology company Moderna, based in the United States.

Visual 1: Infographic: A world map highlighting the countries of origin for major COVID-19 vaccines, showing Covaxin (India), Covishield (UK), Sputnik V (Russia), and Moderna (USA).
Visual 2: Diagram: A comparative illustration of different vaccine platforms, explaining how an inactivated vaccine (Covaxin), a viral vector vaccine (Covishield), and an mRNA vaccine (Moderna) function to create immunity.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Indigenous COVID-19 Vaccine Development as background academic context rather than a clinical decision trigger.
Indigenous vaccine development is critical for a nation's health security and self-reliance, especially during a global health crisis like a pandemic. It ensures a stable supply chain and affordable access for the population.
The ability to develop and manufacture vaccines domestically, like Covaxin, allows for better control over distribution and logistics tailored to the country's specific needs, such as cold chain requirements (Covaxin is stored at 2-8°C).
What if? If India had not developed an indigenous vaccine, its national vaccination program would have been entirely reliant on technology transfers or imports, potentially facing significant delays, higher costs, and supply chain vulnerabilities, which could have hampered the pandemic response.

How to Approach the Question

First, identify the key terms in the question: 'first,' 'indigenous,' and 'India'.
Understand that 'indigenous' means the vaccine was researched and developed within India, not just manufactured or bottled there.
Systematically evaluate each option based on its origin.
Eliminate Sputnik V (Russian) and Moderna (American) as they are clearly foreign-developed.
Differentiate between Covishield and Covaxin. Recall that while Covishield was mass-produced in India, its development was done in the UK. Covaxin was developed by Indian institutions.
Conclude that Covaxin is the only option that fits the definition of an 'indigenous' vaccine.

Concept Tested & Keywords

Q5P65RsfuY7_63QNBnVUxw